Zentalis Pharmaceuticals Financials
| ZNTL Stock | USD 1.76 0.11 5.88% |
Zentalis |
Understanding current and past Zentalis Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Zentalis Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Zentalis Pharmaceuticals' assets may result in an increase in income on the income statement.
Zentalis Pharmaceuticals Stock Summary
Zentalis Pharmaceuticals competes with Sana Biotechnology, Olema Pharmaceuticals, Cullinan Oncology, Monte Rosa, and Design Therapeutics. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US98943L1070 |
| CUSIP | 98943L107 |
| Location | New York; U.S.A |
| Business Address | 1359 Broadway, New |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | zentalis.com |
| Phone | 212 433 3791 |
| Currency | USD - US Dollar |
Zentalis Pharmaceuticals Key Financial Ratios
| Return On Equity | -0.43 | ||||
| Return On Asset | -0.25 | ||||
| Target Price | 6.27 | ||||
| Number Of Employees | 124 | ||||
| Beta | 1.75 |
Zentalis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zentalis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zentalis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zentalis Pharmaceuticals competition to find correlations between indicators driving Zentalis Pharmaceuticals's intrinsic value. More Info.Zentalis Pharmaceuticals Llc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Zentalis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Zentalis Pharmaceuticals Systematic Risk
Zentalis Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Zentalis Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Zentalis Pharmaceuticals correlated with the market. If Beta is less than 0 Zentalis Pharmaceuticals generally moves in the opposite direction as compared to the market. If Zentalis Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Zentalis Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Zentalis Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Zentalis Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Zentalis Pharmaceuticals March 26, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Zentalis Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zentalis Pharmaceuticals Llc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zentalis Pharmaceuticals Llc based on widely used predictive technical indicators. In general, we focus on analyzing Zentalis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zentalis Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 42.4 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 8.0 |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.